Publications by authors named "Haley J VanBeek"
Mol Cancer Ther
November 2021
Article Synopsis
- - M6620 is a selective inhibitor targeting the ATR kinase and is being studied alongside radiation therapy for patients dealing with non-small cell lung cancer (NSCLC) brain metastases, showing potential to enhance treatment effectiveness.
- - Preclinical studies demonstrated that M6620 significantly impacts DNA damage repair processes, leading to increased cancer cell death and improved overall survival in mice compared to radiation therapy alone.
- - The research reveals that DDR pathway alterations in NSCLC tumors correlate with specific genetic mutations and histological types, suggesting a tailored approach for combining M6620 with radiation in current clinical trials (NCT02589522).
